| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review |
Departments of 1 Rheumatology and 2 Oncology, Herlev University Hospital, Herlev, Denmark; and 3 Department of Biology, University of California San Diego, La Jolla, California
Requests for reprints: Julia S. Johansen, Department of Rheumatology Q107, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Phone: 45-4488-4243; Fax: 45-4488-4214. E-mail: julia.johansen{at}post3.tele.dk.
YKL-40, a member of the "mammalian chitinase–like proteins," is expressed and secreted by several types of solid tumors. The exact function of YKL-40 in cancer diseases is unknown and is an important objective of future studies. YKL-40 exhibits growth factor activity for cells involved in tissue remodeling processes. YKL-40 may have a role in cancer cell proliferation, survival, and invasiveness, in the inflammatory process around the tumor, angiogenesis, and remodeling of the extracellular matrix. YKL-40 is neither organ- nor tumor-specific. However, the present retrospective clinical studies of patients with eight different types of primary or advanced solid tumors suggest that serum concentration of YKL-40 may be a new biomarker in cancer patients used as a "prognosticator." Elevated serum YKL-40 is found in a subgroup of patients with different types of solid tumors, including several types of adenocarcinomas, small cell lung carcinoma, glioblastoma, and melanoma. The highest serum YKL-40 is detected in patients with advanced cancer and with the poorest prognosis. In many cases, serum YKL-40 provides independent information of survival. Serum YKL-40 cannot be used as a single screening test for cancer. The use of serum YKL-40 has not received Food and Drug Administration approval for use as a biomarker for cancer or any other disease. Large multicenter retrospective and prospective studies of patients with different types of cancer are required to determine: (a) if serum YKL-40 is a useful prognostic cancer biomarker, (b) if serum YKL-40 can be of value in monitoring patients with cancer in order to provide information about metastases before these are detected by routine methods, and (c) if serum YKL-40 can be useful for screening of cancer together with a panel of other cancer biomarkers and imaging techniques. (Cancer Epidemiol Biomarkers Prev 2006;15(2):194–202)
This article has been cited by other articles:
|
|
 |
|
  J. Kastrup, J. S. Johansen, P. Winkel, J. F. Hansen, P. Hildebrandt, G. B. Jensen, C. M. Jespersen, E. Kjoller, H. J. Kolmos, I. Lind, et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease Eur. Heart J., May 1, 2009; 30(9): 1066 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Johansen, S. E. Bojesen, A. K. Mylin, R. Frikke-Schmidt, P. A. Price, and B. G. Nordestgaard Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population J. Clin. Oncol., February 1, 2009; 27(4): 572 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mitsuhashi, H. Matsui, H. Usui, Y. Nagai, S. Tate, Y. Unno, K. Hirashiki, K. Seki, and M. Shozu Serum YKL-40 as a marker for cervical adenocarcinoma Ann. Onc., January 1, 2009; 20(1): 71 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Biggar, J. S. Johansen, K. E. Smedby, K. Rostgaard, E. T. Chang, H.-O. Adami, B. Glimelius, D. Molin, S. Hamilton-Dutoit, M. Melbye, et al. Serum YKL-40 and Interleukin 6 Levels in Hodgkin Lymphoma Clin. Cancer Res., November 1, 2008; 14(21): 6974 - 6978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Nielsen, C. Erikstrup, J. S. Johansen, C. P. Fischer, P. Plomgaard, R. Krogh-Madsen, S. Taudorf, B. Lindegaard, and B. K. Pedersen Plasma YKL-40: A BMI-Independent Marker of Type 2 Diabetes Diabetes, November 1, 2008; 57(11): 3078 - 3082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Johansen, T. Lottenburger, H. J. Nielsen, J. E. B. Jensen, M. N. Svendsen, G. Kollerup, and I. J. Christensen Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2603 - 2608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Letuve, A. Kozhich, N. Arouche, M. Grandsaigne, J. Reed, M.-C. Dombret, P. A. Kiener, M. Aubier, A. J. Coyle, and M. Pretolani YKL-40 Is Elevated in Patients with Chronic Obstructive Pulmonary Disease and Activates Alveolar Macrophages J. Immunol., October 1, 2008; 181(7): 5167 - 5173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Kolson YKL-40: A Candidate Biomarker for Simian Immunodeficiency Virus and Human Immunodeficiency Virus Encephalitis? Am. J. Pathol., July 1, 2008; 173(1): 25 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Johansen, K. Brasso, P. Iversen, B. Teisner, P. Garnero, P. A. Price, and I. J. Christensen Changes of Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment for Metastatic Prostate Cancer Are Related to Survival Clin. Cancer Res., June 1, 2007; 13(11): 3244 - 3249. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
